Abstract
Background: To evaluate in patients on a liver transplantation waiting list, potential biomarkers of the base calcineurin pathway activity in a new model of non-stimulated peripheral blood mononuclear cells (PBMC) and ex vivo response to tacrolimus.
Methods:
The calcineurin pathway activity was explored ex vivo in stimulated and nonstimulated PBMC from 19 patients. The inhibition of NFAT1 + translocation to PBMC, expression of intracellular IL-2 and membrane CD25 in different T cells subsets in basal conditions and after exposure to tacrolimus at pharmacological levels were measured by multiparametric flow cytometry. We also studied the influence on the individual response of polymorphisms in 3 key genes of the calcineurin pathway: PPIA, PPP3CA
and IL2RA.
Results: All pharmacodynamics profiles closely fitted an I/I max sigmoid model.
Interindividual variability was higher in non-stimulated than in stimulated conditions, as well as in the presence of tacrolimus. IL-2 + CD8 + cells at tacrolimus I max showed the highest interindividual variability, suggesting its usefulness as a biomarker of individual tacrolimus effects integrating many different sources of regulation and variability.
Moreover, in the absence of tacrolimus, patients with end stage liver disease exhibited lower NFAT1 translocation and T cell activation as compared to healthy volunteers from a previous study in similar conditions. Multivariate statistical analysis showed strong and significant associations between tacrolimus pharmacodynamic parameters and two polymorphisms in the gene coding cyclophilin A (rs8177826 and rs6850).
Conclusion:
This study showed the feasibility of using non-stimulated PBMCs to explore the calcineurin pathway in more physiologic conditions and points towards potential biomarkers for tacrolimus pharmacodynamics monitoring. T cell cytokines and surface activation markers have been investigated as markers of TAC pharmacodynamics in individuals (3, 4, 5) . The recently published consensus on biomarkers to adjust ISD in transplantation encompasses proteins that might predict the risk of rejection and tolerance; biomarkers of the individual response to ISD; pharmacogenetic (PG) polymorphisms influencing ISD PK and PD; as well as BM associated with graft dysfunction or injury (6) .
Previous studies by Canivet et al. (7) using whole blood from cirrhotic patients on the waiting list for liver transplantation (LT) found an increased expression of intralymphocyte interleukin 2 (IL-2) and tumor necrosis factor alpha (TNFα) and a decreased expression of the transferrin receptor (CD71) and CD25 (also called IL2Rα, the interleukin 2 receptor alpha-chain subunit) as compared to healthy volunteers (HV).
However, in patients with hepatitis C virus infection (HCV), both T cell activation and proliferation were upregulated, suggesting that this condition would favor a switch in the immune response. We previously explored TAC PD ex-vivo along the calcineurin (CaN) pathway in HV (8) .
The aim of this study in patients on the waiting list for LT was to investigate ex-vivo the basal calcineurin pathway activity in a new model of non-stimulated peripheral blood mononuclear cells (PBMC), its response to increasing concentrations of TAC and the influence of end-stage liver disease (ESLD) and target gene polymorphisms on the inter-individual pathophysiological and pharmacodynamic variability. liver transplantation (WLP) were enrolled if they were free from corticosteroids, immunosuppressive drug or interferon gamma therapies, were not candidates for combined hepatorenal transplantation, and if they gave informed consent in writing.
MATERIALS AND METHODS

STUDY DESIGN AND SUBJECTS
One blood draw was collected from all the patients, on different days over a period of 5 months.
PHARMACODYNAMIC STUDY
PBMC were obtained using lymphocyte density-gradient separation of fresh blood collected on sodium heparin, re-suspended in supplemented RPMI and counted in a cell-counter.
For each set of markers, aliquots of PBMC in supplemented RPMI were incubated exvivo for 30min at 37°C in a humidified atmosphere at 5% CO 2 with 0 to 50ng/ml TAC. , intracellular IL-2 expression in CD4  + and CD8   +   T cells and CD25  High expression at the surface of CD3  + , CD4  + , and CD8  + T cells, were determined by multiparametric flow cytometry (8) .
NFAT1 translocation to PBMC nuclei
For each whole blood sample, one aliquot of 1 million cells in 100 µl of supplemented RPMI was analyzed without mitogen stimulation or tacrolimus addition (so-called "physiological" or "non-stimulated -NS-values" thereafter), while other aliquots were analyzed with and without tacrolimus after incubation with: 50 ng/ml PMA and 2.5 µg/ml calcium ionophore at 37°C in a humidified atmosphere with 5% CO 2 , for 30 minutes for NFAT1 and for 5h plus 1 µg/ml of Golgi Plug for IL-2; 7.5 µg/ml 
RESULTS
Nineteen patients from the liver transplantation waiting list (13 men and 6 women) were enrolled. Their indication for LT and demographic characteristics are summarized in Table I .
The mean TAC PD parameters measured in fresh PBMC samples are shown in Table II, while individual values can be found in Supplemental Table S2 . The median and extreme numbers of events detected in non-stimulated and stimulated conditions for the different PD parameters are listed in Supplemental Table S3. NFAT1 in PBMC nuclei, intracellular IL-2 and membrane CD25 expression in each of the T cell subpopulations studied all adequately fitted I/I max sigmoid models (figure 1).
Precise PD parameters could be derived from these well-fitted inhibition curves ( figure   S4 ). Large inter-individual variability was found for all biomarkers, in NS (unstimulated, physiological) (CV = 59-265%), I 0 (no TAC exposure, stimulated conditions) (CV= 56-106%), IC 50 (CV = 122-174%) and I max (CV = 94-230%)
conditions. At TAC I max , NFAT1 in PBMC nuclei, IL-2 in CD8 + T cells and CD25 High in T cells showed incomplete inhibition (Table II) and huge inter-individual variability, IL-2 exhibiting the largest (CV = 230% and 190% for CD4 + and CD8 + cells, respectively).
TAC IC 50 augmented along the CaN pathway, from a geometric mean of 0.6 ng/ml for NFAT1 up to 1.3 ng/ml for CD25 High CD8 + (Table II) In multivariate analysis, several significant associations were found between SNPs and either the physiological activity of the calcineurin pathway or TAC PD biomarkers (Table III) 
DISCUSSION
To the best of our knowledge, this is the first time that the CaN/NFAT signaling cascade, tacrolimus inhibitory signal transmission and the influence of gene variants along this cascade have been investigated in patients. This study follows a similar design as a previous study in healthy volunteers (8) , except that herein we also explored the physiological activity of the calcineurin pathway and its variability in non- Per se, the determination of the "physiologic" values of the biomarkers is unusual and innovative and it showed that they were all measurable in the absence of stimulation, apart from IL-2 in CD4 + and CD25 in CD8 + T cells whose levels were near or below the detection limit of the flow cytometer technique (LOD = 0.15% for IL-2 in CD4 + and 0.10% for CD25 in T cell subsets). In the Supplemental Table S3 , we listed the numbers of events analyzed in NS and stim conditions without TAC exposure, which illustrate the feasibility of this novel approach, hence of novel potential biomarkers.
"Physiologic" readouts reflect the basal state of the patient and are free from artificial influences brought by mitogenic stimulation, which can modify cell expression, while stimulated biomarkers may better mirror the maximum capacity of the patient immune response. Potential biomarkers obtained in either condition may serve to monitor TAC PD.
Comparisons of I 0 levels measured in identical conditions in HV (8) and WLP are shown in figure 3 , showing that they were lower for all BM in the former, except for IL- This study only enrolled a small number of patients, but the ex-vivo experiments are very long, cumbersome and costly and it is unlikely that a much larger patient group could be studied to this extent. The methods employed can hardly be considered for the pharmacodynamics monitoring of tacrolimus in routine, but they allowed us to explore signal transduction along the calcineurin pathway rather than a single predefined biomarker, and to compare our results with those previously obtained in healthy volunteers or that we will obtain in transplanted patients, as planned in the 3PIGREF
trial. Also, PBMC were incubated with pure tacrolimus, thus the influence of its eight known metabolites was not considered (19) ; however, their pharmacodynamics, potential therapeutic and adverse effects have only been poorly explored so far.
In summary, non-stimulated measures may be suitable to assess the physiological activity of calcineurin signaling, while measures after PBMC ex vivo stimulation might rather evaluate the pathway maximal capacity. IL-2 in CD8 + cells at TAC I max might be a useful biomarker of tacrolimus effects owing to its greatest variability, while based on the literature, inhibition of NFAT1 translocation to PBMC nuclei might be a better biomarker of immunological competence linked to infections. The influence of polymorphisms in cyclophilin A on the pathway in the absence of TAC was impressive, in both non-stimulated and stimulated conditions. Our patients with ESLD exhibited a decrease in practically all the biomarkers studied (except T cytotoxic function) as compared to healthy subjects. Whether these biomarkers are predictive of graft rejection or other clinical outcomes is the object of an on-going prospective follow-up of transplanted patients as part of the 3PIGREF trial. 
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SUPPLEMENTAL MATERIAL AND METHODS
CHEMICALS AND REAGENTS
During PBMC incubation, we added RPMI 1640 medium with 10% of heat-inactivated Fetal Bovine Serum, 10% of PenStrep 5000U/ml of penicillin, 5000 µg/ml of streptomycin and 10% of L-Glutamine 200 mM 1X (Invitrogen, France). For incubation times longer than 24h, we also added beta-mercaptoethanol (Invitrogen, France).
White blood cells (WBC) yields measured using a calibrated cell counter were at least 10 6 in each well, sufficient for all our experiments. We did not optimize further our PBMC separation technique, as it fulfilled the MIQUE checklist requirements.
Ex-vivo Tacrolimus exposure
For each set of markers, aliquots of PBMC in supplemented RPMI were incubated exvivo for 30min at 37°C in a humidified atmosphere at 5% CO 2 (in 96-well sterile plates) with 0 to 50 ng/ml of TAC in RPMI 1640.
Cell activation strategy
For IL-2 and NFAT1 activation, we chose PMA/ionomycin because PMA exerts its 
NFAT1 translocation to the nucleus of PBMC cells
To assess the degree of NFAT1 translocation into the nucleus, an indirect (secondary)
antibody staining technique was employed to improve dye sensitivity to signal amplification. The procedure started with aliquots of 1 million cells in 1000 µl of supplemented RPMI, treated with 0 -50 ng/ml TAC during 30 min at 37°C and 5% 
Intracellular IL-2 expression in CD4 + and CD8 + T cell subsets
After TAC exposure or directly after PBMC separation, aliquots of 1 million cells in 100 µl of supplemented RPMI were stimulated with 50 ng/ml PMA, 2.5 µg/ml calcium ionophore and 1 µg/ml Golgi Plug for 5h at 37°C in a humidified atmosphere with 5% Antibodies were titrated to optimize the best ratio of fluorescence and fluorescence- 
PHARMACODYNAMIC ASSAYS
We previously studied the analytical and intra-individual variability of our methods for all of our pharmacodynamic markers using PBMC from healthy volunteers enrolled in For the analytical variability, coefficients of variation at physiological levels (I 0 ) were always less than 9%, while those at 5 ng/ml TAC (i.e., approximately at TAC IC 50 concentration) were somewhat higher, ranging from 1.5 to 11%, with the notable exception of IL-2 in CD8 + cells which apparently peaked at 62%. Indeed, the smaller the acquired values, as in the case of IL-2 + CD8 + expression at 5 ng/ml TAC (<2% and often undetectable), the larger the imprecision of the readout. The intra-individual variability in healthy volunteers ranged from 3.2 to 6.5% for I 0 and from 8.6 to 17% for IC 50 , except for NFAT1 (IC 50 CV% = 50%)
PHARMACOGENETIC STUDY
Genomic DNA was isolated from peripheral blood EDTA tubes using a commercial kit (the PureLink™ Genomic DNA, Invitrogen, USA in Montevideo and the QIAamp DNAMini Kit 51306 from Qiagen, France) according to the manufacturer's protocol.
The DNA concentration was quantified using a NanoDrop 1000 spectrophotometer (Thermo Scientific, USA).
DNA amplifications were performed in a total volume of 20µL containing 50 ng of genomic DNA, 0.8 mM of each dNTP (Fermentas), 0.2 mM of each primer, 2mM
MgCl 2 , 5% DMSO (Bio Basic Inc), and 0.3U Taq DNA polymerase (Invitrogen).
The thermal cycler program was set for an initial denaturation at 95°C for 5min, followed by 30 cycles of 30s at 95°C, 30s at the annealing temperature (Tm), 30s at 72°C and a final extension for 5min at 72°C.
Tm was set at 54ºC for the amplification of PPP3CA and FKB1A fragments, and at 55ºC and 58°C when amplifying the PPP3R1 and PP1A promoter regions, respectively.
Promoters sequencing procedure
For DNA sequencing we used: the PCRx Enhancer system 11495-017 (10x PCRx Rxn Customized primers were provided by Eurofins MWG Operon, Germany.
For each promoter region studied, the PCR reaction involved a first denaturation step at 94°C for 2min, followed by 35 cycles of denaturation at 95°C for 30sec, annealing at 55°C for 30sec, and extension at 68°C for 1min. The last step consisted of a final denaturation at 72°C for 7min. The reaction mix was composed of 5µL of PCRx The PCR products to be sequenced (PPP3CA, PPP3R1 and PP1A) were purified using a 2% agarose gel (QIAquick Gel Extraction Kit, Qiagen, USA).
The sequencing reactions were performed by the Macrogen Service Center (Republic of Korea) or the Institute of Clinical Molecular Biology, Christian-Albrechts University Hospital Schleswig Holstein, Kiel (Germany).
Genotyping assays
The region containing the c.-215C>A FKBP1A polymorphism was digested with 0.3U of AvaI (Fermentas) for 3h at 37ºC and separated by electrophoresis through a 6% polyacrylamide gel; afterwards the product was exposed to silver nitrate 0.2%. All primer sequences are available on request.
